US20240350437A1 Patent on gamma-hydroxybutyrate compositions

Patents US20240350437A1 and US20240350438A1 – Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state – Google Patents relates to pharmaceutical compositions and systems designed to provide controlled and consistent drug release for oral administration. The invention addresses challenges associated with delayed or multi-stage drug delivery, particularly for active pharmaceutical ingredients (APIs) with complex absorption profiles or sensitivity to environmental factors like pH. More specifically, gamma-hydroxybutyrate (GHB) is employed as API. GHB is a drug from the group of sedatives that is approved for the treatment of narcolepsy with cataplexy in adults.

The core of the patent involves multiparticulate formulations, in which small spherical particles or granules are coated with APIs and polymers. These coatings are designed to modulate drug release rates, enabling gradual, sustained, or targeted delivery in the gastrointestinal tract. This technology is particularly useful for achieving precise therapeutic effects, minimizing dosing frequency, and reducing potential side effects caused by rapid drug release.

The document highlights advancements in coating techniques and the use of stabilizing agents to improve the integrity and functionality of the drug delivery system. It also discusses scalability and manufacturing efficiency, making these formulations suitable for large-scale production while maintaining consistency in dosage and performance.

Potential applications include treatments for chronic conditions or drugs that require precise dosing regimens. The invention provides flexibility in formulating for a range of APIs, allowing for customization to meet specific therapeutic needs. By enabling controlled drug release, the technology enhances medication adherence and efficacy, benefiting both patients and healthcare providers.

What is the role of MCC pellets as drug carrier of gamma-hydroxybutyrate compositions?

This patent US20240350437A1 focuses on an innovative approach to creating multiparticulate pharmaceutical formulations designed for oral administration. The patent introduces CELLETS® which are a key component of the drug delivery system. CELLETS® are small, uniform spherical particles made of inert microcrystalline cellulose (MCC), that act as carriers for active pharmaceutical ingredients (APIs). These particles provide an optimal surface for drug layering, facilitating precise drug release profiles. In this patent, these types of CELLETS® are applicable:

  • CELLETS® 90
  • CELLETS® 100
  • CELLETS® 127

The invention addresses challenges in achieving controlled drug release, particularly for APIs requiring multi-step or delayed absorption. By coating these MCC carriers with specific polymers and APIs, the system allows for tailored drug release at targeted points in the gastrointestinal tract. This is especially beneficial for drugs with narrow therapeutic windows or those sensitive to pH levels.

The patent emphasizes advancements in coating techniques and formulation stability, ensuring high reproducibility and efficient manufacturing processes. The resulting multiparticulate system supports dosage flexibility, reduced side effects, and improved patient adherence compared to conventional tablet or capsule forms.

The invention has implications for developing treatments for chronic conditions, where consistent and predictable drug release is critical. The application of CELLETS® in this context highlights their versatility and potential to enhance the efficacy and safety of oral drug delivery systems.

Document information

Document Type and Numbers:

  • (“Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state”).
  • US20240350438A1 (“Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state”).
Kind Code: A1

Inventors:

Julien Grassot, Cendrine Grangeon, Jordan Dubow

Disclaimer

This text was partly generated by chatGPT engine version GPT‑4o, on Nov 21, 2024. Image was generated with Adobe Firefly.